Jeffrey Liu, MD
Neurology · Honolulu, HINPI 1750359709
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 471 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations.
Across 471 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- UCB, Inc.$1K
- Sunovion Pharmaceuticals Inc.$1K
- Teva Pharmaceuticals USA, Inc.$984
- Pfizer$867
- Biohaven Pharmaceuticals, Inc.$442
- plus $2K from 22 others
What the payments were for
- Food & beverage$7,89396%
- Education$3384%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $1,576 |
| UCB, Inc. | 67 | $1,397 |
| Sunovion Pharmaceuticals Inc. | 72 | $1,222 |
| Teva Pharmaceuticals USA, Inc. | 42 | $984 |
| Pfizer | 67 | $867 |
| Biohaven Pharmaceuticals, Inc. | 34 | $442 |
| Biohaven Pharmaceutical Holding Company Ltd. | 32 | $366 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $281 |
| Upsher-smith Laboratories LLC | 6 | $150 |
| Lundbeck LLC | 7 | $141 |
| Acadia Pharmaceuticals Inc | 5 | $113 |
| Amgen(2 entities) | 3 | $83 |
| Idorsia Pharmaceuticals US Inc | 5 | $78 |
| Amneal Pharmaceuticals LLC | 4 | $76 |
| Novartis | 4 | $62 |
| Arbor Pharmaceuticals, Inc. | 5 | $61 |
| Tanabe Pharma America, Inc. | 3 | $59 |
| Livanova USA, Inc. | 2 | $38 |
| Argenx US, Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Genentech USA, Inc. | 1 | $28 |
| Abbott | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $20 |
| GE HealthCare | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Neurelis, Inc. | 1 | $16 |
How this compares
$8,231 in reported general payments places this provider in the 75th percentile of 54 neurology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 14 | $80,288 |
| Nurtec OdtRimegepant Sulfate | 19 | $76,103 |
| NuplazidPimavanserin Tartrate | 14 | $68,828 |
| BriviactBrivaracetam | 30 | $55,339 |
| BrilintaTicagrelor | 55 | $46,633 |
| HorizantGabapentin Enacarbil | 19 | $35,897 |
| NeuproRotigotine | 19 | $34,974 |
| GocovriAmantadine Hcl | 13 | $21,049 |
| UbrelvyUbrogepant | 13 | $20,139 |
| RytaryCarbidopa/Levodopa | 13 | $17,494 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $13,322 |
| Duloxetine Hcl | 142 | $11,756 |
| Memantine Hcl | 127 | $9,873 |
| Galantamine ErGalantamine Hbr | 98 | $9,745 |
| EliquisApixaban | 15 | $8,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Neupro | $1,397 | $90,31349 claims |
| PfizerNurtec Odt, Eliquis | $867 | $84,79734 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $984 | $80,28814 claims |
| Acadia Pharmaceuticals IncNuplazid | $113 | $68,82814 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $61 | $35,89719 claims |
| AbbVieUbrelvy, Linzess | $1,576 | $27,60827 claims |
| Amneal Pharmaceuticals LLCRytary | $76 | $17,49413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 54 neurology providers in Hawaii.
Other neurology in Honolulu
- Leo MaherHonolulu$382K
- Leah RidgeHonolulu$47K
- Melvin YeeHonolulu$32K
- Kevin KimataHonolulu$24K
- Terry ShimamotoHonolulu$24K
- Michael RussoHonolulu$20K
- Kore LiowHonolulu$15K
- Fay GaoHonolulu$13K
- Sarah GranerHonolulu$10K
- Monique CanonicoHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.